Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Journal of Gastroenterology
Published in: Clinical Journal of Gastroenterology 6/2016

01-12-2016 | Case Report

Acute exacerbation of irritable bowel syndrome prevented by prn oral triptan

Authors: Benjamin N. R. Cheyette, Sarah N. R. Cheyette

Published in: Clinical Journal of Gastroenterology | Issue 6/2016

Login to get access

Abstract

We report a case of irritable bowel syndrome (IBS), diarrhea subtype, characterized by daily ‘morning rush’ and episodic acute exacerbations brought on by common IBS trigger foods including insoluble fiber, red wine and large/rich meals. The patient also had a history of migraine headaches, and a family history suggesting a common diathesis for both disorders. Given hypothesized contributions to IBS from dysregulation of the enteric serotonergic system, a trial of low-dose triptan medication was implemented in the context of the patient’s known IBS triggers, with highly satisfactory results.
Literature
1.
Hungin AP, Chang L, Locke GR, Dennis EH, Barghout V. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther. 2005;21:1365–75.CrossRefPubMed
2.
Mearin F, Lacy BE, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393–407.CrossRef
3.
4.
Tack J, Vanuytsel T, Corsetti M. Modern management of irritable bowel syndrome: more than motility. Dig Dis. 2016;34:566–73.CrossRefPubMed
5.
Shah SL, Lacy BE. Dietary interventions and irritable bowel syndrome: a review of the evidence. Curr Gastroenterol Rep. 2016;18:41.CrossRefPubMed
6.
McKenzie YA, Bowyer RK, Leach H, et al. British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet. 2016;29(5):549–75.CrossRefPubMed
7.
Staudacher HM, Irving PM, Lomer MC, Whelan K. Mechanisms and efficacy of dietary FODMAP restriction in IBS. Nat Rev Gastroenterol Hepatol. 2014;11:256–66.CrossRefPubMed
8.
Molina-Infante J, Serra J, Fernandez-Banares F, Mearin F. The low-FODMAP diet for irritable bowel syndrome: lights and shadows. Gastroenterol Hepatol. 2016;39:55–65.CrossRefPubMed
9.
Farzaei MH, Bahramsoltani R, Abdollahi M, Rahimi R. The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments. J Neurogastroenterol Motil 2016. doi:10.​5056/​jnm16001.PubMedPubMedCentral
10.
Sikander A, Rana SV, Prasad KK. Role of serotonin in gastrointestinal motility and irritable bowel syndrome. Clin Chim Acta. 2009;403:47–55.CrossRefPubMed
11.
Garvin B, Wiley JW. The role of serotonin in irritable bowel syndrome: implications for management. Curr Gastroenterol Rep. 2008;10:363–8.CrossRefPubMed
12.
Corsetti M, Whorwell P. Novel pharmacological therapies for irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. 2016;10:807–15.CrossRefPubMed
13.
Bundeff AW, Woodis CB. Selective serotonin reuptake inhibitors for the treatment of irritable bowel syndrome. Ann Pharmacother. 2014;48:777–84.CrossRefPubMed
14.
Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol. 2002;59:1084–8.CrossRefPubMed
Metadata
Title
Acute exacerbation of irritable bowel syndrome prevented by prn oral triptan
Authors
Benjamin N. R. Cheyette
Sarah N. R. Cheyette
Publication date
01-12-2016
Publisher
Springer Japan
Published in
Clinical Journal of Gastroenterology / Issue 6/2016
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-016-0689-9

Other articles of this Issue 6/2016

Clinical Journal of Gastroenterology 6/2016 Go to the issue

Case Report

The prospect of endoscopic submucosal dissection for early anal canal squamous cell carcinoma

Case Report

Gastric plexiform schwannoma in association with neurofibromatosis type 2

Case Report

Esophageal stricture after endoscopic submucosal dissection treated successfully by temporary stent placement

Case Report

Twelve-year natural history of a gastric adenocarcinoma of fundic gland type

Case Report

Acute esophageal necrosis

Case Report

Use of an over-the-scope clipping device for closure of a jejuno-sigmoid fistula: a case report with long-term follow-up
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits